Form 4 Filing for Dyne Therapeutics, Inc.

This filing details stock transactions by Kersten Dirk, a director at Dyne Therapeutics, Inc. On April 17, 2026, 211,974 shares of Common Stock were sold at a weighted average price of $20.2916, pursuant to a Rule 10b5-1 trading plan. Following this transaction, 4,332,799 shares remained. On April 20, 2026, an additional 125,274 shares of Common Stock were sold, also under a Rule 10b5-1 plan, at a weighted average price of $20.0672. After this second transaction, the total number of shares held was 4,207,525. The shares are held indirectly through ForDyne B.V., with ownership and control details involving various Forbion entities and partners. Mr. Dirk disclaims beneficial ownership except to the extent of his pecuniary interest.